
Is PDRN a peptide? Salmon DNA vs GHK-Cu, explained
A reader asked whether PDRN, the salmon DNA skin injectable trending in K-beauty, is a peptide. Short answer: no. Here is what it actually is, how it compares to GHK-Cu copper peptides, and which one makes sense for your skin.
For educational purposes only. This article explains ingredient science and is not medical or dermatological advice. Rejuran and other PDRN injectables are not FDA approved in the United States as of April 2026, so US clinics offering them are doing so off-label. Do not use PDRN if you have a diagnosed salmon allergy: trace source material can remain after purification. If you are considering an injectable treatment, consult a licensed dermatologist or plastic surgeon, and always verify a clinic's credentials and the sourcing of any injectable product.
The short answer: PDRN is not a peptide
PDRN stands for polydeoxyribonucleotide, a chain of DNA units. A peptide is a chain of amino acids. Both are molecular chains, but they are built from different chemical alphabets, and your skin cells understand both. The purification process for PDRN deliberately strips out residual peptides to avoid allergic reactions.
PDRN stands for polydeoxyribonucleotide. That is a long word, so let us break it apart. "Poly" means many, and "deoxyribonucleotide" means the chemical unit that makes up DNA. So PDRN is literally many DNA units linked together in a chain. A peptide is a different kind of chain: it is made of amino acids, the building blocks of proteins. Same idea (a chain of small pieces), different pieces.
Think of it like language. Both English and Spanish are languages, but they use different alphabets and different grammar. Peptides and PDRN are both molecular chains, but they speak different chemical alphabets. Your skin cells happen to understand both.
The confusion makes sense. PDRN is often sold under names like Rejuran, Plinest, and Mastelli, and it is marketed alongside peptides on skincare websites. But the molecules are chemically distinct. The purification process for PDRN actually removes any residual peptides on purpose, because leftover protein fragments could trigger an allergic reaction in the skin [1].
So what is PDRN actually made of?
PDRN is fragmented DNA extracted from the sperm cells of salmon trout or chum salmon. Enzymes chop the raw DNA into shorter pieces, then purification removes more than 95 percent of proteins and peptides. What remains is DNA fragments typically spanning 50 to 1500 kilodaltons, far larger than a copper peptide.
PDRN is fragmented DNA that comes mostly from the sperm cells of salmon trout or chum salmon. Yes, the "salmon DNA" headlines are accurate. The manufacturer takes raw fish DNA, chops it into shorter pieces using enzymes (enzymes are just tiny molecular scissors), and then purifies those pieces until more than 95 percent of the proteins and peptides are gone. What is left behind is a clean mixture of DNA fragments typically spanning 50 to 1500 kilodaltons in size [2].
A kilodalton is just a unit of weight for very small things (1 dalton is roughly the weight of one hydrogen atom, and 1 kilodalton is 1000 of those). For comparison, GHK-Cu, a well-studied copper peptide, weighs about 0.4 kilodaltons. That is a big size difference, and it matters for how each molecule gets into your skin (more on that below).
You may also see the term polynucleotide biorevitalization or just PN. The two terms are closely related, and the 2025 review that mapped this field proposes drawing the line at 1500 kilodaltons: shorter chains are properly called PDRN, longer ones PN [2]. If you see Rejuran, Plinest, or Mastelli on a clinic menu, they are all running on the same underlying mechanism. Rejuran is to PDRN what Ozempic is to semaglutide, a brand built around the active ingredient.
What does PDRN actually do in your skin?
PDRN binds the adenosine A2A receptor on fibroblasts, the cells that manufacture collagen and elastin. That triggers three things: more collagen output, calmer local inflammation, and new small blood vessels. A second route recycles the DNA fragments through the salvage pathway, freeing the cell to spend energy on repair.
Your skin has cells called fibroblasts. These are the workers that manufacture collagen and elastin, the two proteins that give young skin its bounce and firmness. As you age, fibroblasts slow down. Wrinkles, thin skin, and slow wound healing all trace back to less-productive fibroblasts.
PDRN wakes those workers up. Specifically, it binds to a receptor on the fibroblast surface called the adenosine A2A receptor. You can think of a receptor as a docking slot on the outside of the cell: when the right molecule clicks into the slot, the cell changes what it is doing. When PDRN clicks into the A2A slot, three things happen. The fibroblast starts making more collagen, it calms inflammation around itself, and it helps grow new tiny blood vessels, which means better nutrient delivery to the skin [3].
There is also a second mechanism that is actually kind of elegant. The DNA fragments in PDRN can be recycled by the cell through something called the salvage pathway. Cells are thrifty: rather than always building DNA components from scratch, they will reuse fragments when available. PDRN essentially hands the fibroblast a stack of pre-made parts, which frees the cell up to put more energy into making collagen and repairing itself [4].
How GHK-Cu compares: a real peptide with different strengths
GHK-Cu is a tripeptide, three amino acids bound to a copper ion, first identified in human blood plasma in 1973. Rather than signalling one receptor, it changes which genes are switched on across thousands of networks. At roughly 0.4 kilodaltons it is small enough to penetrate skin from a topical serum.
GHK-Cu is where peptides enter the conversation. The name is short for glycyl-L-histidyl-L-lysine bound to a copper ion. That literally just describes its recipe: three amino acids (glycine, histidine, lysine) linked in a tiny chain, with one atom of copper attached. The full molecule is only three amino acids long, which is why it is called a tripeptide.
GHK-Cu was first identified in human blood plasma in 1973, and it has been studied in dermatology for decades. The copper peptide works at a more fundamental level than PDRN: instead of telling fibroblasts to produce more collagen, it goes into the cell and changes which genes are turned on or off. One analysis mapped GHK-Cu against over 4000 genes involved in tissue remodeling, antioxidant defense, and collagen synthesis. It nudged activity on all of those networks [5].
Because GHK-Cu is so small (remember, 0.4 kilodaltons versus PDRN's 50 to 1500), it can actually penetrate skin from a topical serum. That is a huge practical difference. You can buy a GHK-Cu serum online for under $30 and apply it at home. PDRN, because the molecule is so much larger, has to be injected directly into the dermis (the layer of skin below the surface where fibroblasts live) to have a real effect. That means a clinic visit, a trained injector, and several hundred dollars per session.
Head-to-head: what actually matters for your decision
Both ingredients raise collagen production, calm inflammation, and improve texture over weeks. They differ on delivery, evidence, regulation, and cost. PDRN owns one clean phase III win against hyaluronic acid filler; GHK-Cu owns decades of dermatology literature and gene-expression data, at roughly a twentieth of the price.
Both ingredients increase collagen production, calm inflammation, and improve skin texture over several weeks of consistent use. Where they differ is how you get them in, how strong the evidence is, and how much they cost.
For evidence, PDRN has the cleaner clinical win in a specific scenario. A phase III randomized double-blind trial published in 2014 matched a polynucleotide filler against a leading hyaluronic acid filler for crow's feet (the fine lines near the outer eye). After a course of treatments, the polynucleotide group showed greater elasticity and collagen density and measurably smaller wrinkle depth [6]. GHK-Cu does not have a head-to-head trial that direct, but it has a much larger body of general dermatology literature going back to the 1980s, plus formal gene-expression data that PDRN does not have.
That single trial is worth keeping in proportion. A 2024 review of polynucleotides across aesthetic medicine found the human evidence genuinely mixed: some studies showed meaningful gains in skin elasticity and hydration, while others reported limited or no benefit, and the authors concluded that more research is needed to establish where these treatments actually help [7]. One strong trial in one indication is not the same as a settled ingredient.
For regulation, there is an asymmetry worth knowing. Rejuran injectables are not FDA approved in the United States as of April 2026. They are legal in South Korea, parts of Europe, and much of Southeast Asia, and some US clinics offer them off-label. GHK-Cu is not a regulated drug in the US at all: it is classified as a cosmetic ingredient, which is why you can buy it on Amazon. Neither status is a red flag by itself, but if you want an injectable with full FDA oversight, Rejuran is not that today.
For cost, topical GHK-Cu serum runs $20 to $80 per bottle and lasts roughly two months. A Rejuran treatment course in the US, where clinics offer it off-label, typically runs $500 to $1000 per session with 3 to 4 sessions suggested before results are assessed. Those are market prices rather than a published figure, but the gap is the point: it is a 15 to 20 times cost difference for your first year.
So which one should you consider?
Honestly, it depends on three things: your actual goal, how reactive your skin is, and whether your budget and needle tolerance can absorb clinic visits. Rather than guessing, the decision helper below asks those three questions and points you to PDRN, GHK-Cu, both, or neither, with the reasoning shown.
Honest answer: it depends on your goal, your budget, and how comfortable you are with needles. Rather than guessing, the tool below walks you through the three questions that actually determine the answer. Pick your main goal, how your skin behaves, and your budget range, and it will point you to PDRN, GHK-Cu, both, or neither with the reasoning spelled out.
Want the full picture on GHK-Cu?
The GHK-Cu mastery course covers the mechanism, the evidence, and how to read a protocol.
The bigger picture: your skin cares about signaling, not labels
Both molecules work because they send signals to skin cells, and your skin does not care whether a signal arrived as a peptide, a DNA fragment, or a retinoid. The useful question is not "is this a peptide?" but "does this signal the thing I want, and can it reach the right cells?"
Here is the punchline that matters more than the peptide-versus-DNA technicality. Both PDRN and GHK-Cu work because they send signals to your skin cells. Your skin does not know (or care) whether the signal came from a peptide, a DNA fragment, a growth factor, or a retinoid. What matters is whether the signal reaches the right cells and tells them to do something useful.
That framing is why the question "is this a peptide?" is less useful than "does this signal the thing I want?" Peptides get most of the marketing because the word sounds scientific and clean. PDRN gets the hype in 2026 because it sounds exotic and novel. In terms of what actually makes skin better, both categories are part of the same bigger toolkit of cellular signaling molecules. Ingredients that have been around a long time (retinoids, vitamin C, niacinamide) work through completely different signals and still get results. PDRN and GHK-Cu are not magic, they are just well-characterized ways of nudging fibroblasts in the right direction.
Skin quality is also affected by factors that have nothing to do with which ingredient you apply. Chronically elevated cortisol accelerates collagen breakdown and slows wound repair, the same fibroblast pathways both PDRN and GHK-Cu try to upregulate. If stress-related skin changes like puffiness, adult acne, or slow healing are part of your picture, the cortisol face guide covers the mechanism and what actually helps. Separately, advanced glycation end-products from a high-sugar diet create cross-links in collagen that neither ingredient can reverse; the sugar face guide explains that pathway and how to reduce it upstream. For context on where injectable treatments like Botox sit relative to PDRN on the same clinical evidence spectrum, the guide to how Botox works covers the neuromuscular mechanism and evidence tier.
If you want the full mechanism and clinical evidence for GHK-Cu, our GHK-Cu mastery course covers the 4000-gene network, the specific wound-healing pathways, and every published study on topical versus injected delivery. For the peptide side of the equation, that is the deepest reference we have. If you are starting from scratch, the free foundations course covers how peptides work before you spend anything.
Frequently asked questions
No. PDRN (polydeoxyribonucleotide) is a chain of nucleotides, the building blocks of DNA. A peptide is a chain of amino acids, the building blocks of proteins. They use different molecular alphabets. The purification process for PDRN specifically removes any residual peptides to prevent allergic reactions.
PDRN is made of fragmented DNA (typically 50 to 1500 kilodaltons) extracted mainly from the sperm cells of salmon trout or chum salmon. The extraction process uses enzymes to chop the raw DNA into shorter usable pieces, then filters out more than 95 percent of any proteins and peptides to avoid immune reactions. What remains is purified deoxyribonucleotide fragments suspended in a sterile solution.
Rejuran is a brand name for a PDRN-based injectable made in South Korea. PDRN is the underlying molecule. Polynucleotide biorevitalization (sometimes abbreviated PN) is the broader category name, and a 2025 review proposes separating PDRN from PN at a 1500 kilodalton chain length. In short, Rejuran is to PDRN what Ozempic is to semaglutide, a brand built around the active ingredient.
No. As of April 2026, Rejuran injectable treatments are not FDA approved in the United States. They are widely used in South Korea, parts of Europe, and Southeast Asia. Some US clinics still offer them off-label, but the regulatory status matters for safety oversight and insurance coverage. GHK-Cu, by contrast, is classified as a cosmetic ingredient and is sold over the counter in serums.
They work on different pathways and do not compete. PDRN activates an adenosine A2A receptor (think of it as a specific docking slot on the cell surface) while GHK-Cu modulates thousands of genes directly inside the cell. There is no trial testing the combination, so anyone layering them is going beyond the published evidence. If you are considering both alongside a clinic treatment, that sequencing question belongs with the practitioner doing the injecting, not with a website.
PDRN has the stronger single result for wrinkle depth, because it is injected directly into the dermis (the active layer of skin under the surface) and won a phase III trial against hyaluronic acid filler for crow's feet. GHK-Cu works topically and has more decades of research behind it. For practical anti-aging on a budget, GHK-Cu serum is the easier entry point. PDRN means clinic visits, several hundred dollars per session, and a broader evidence base that reviews still describe as mixed.
The most common reported side effects are mild redness, swelling, or small bumps at injection sites that usually resolve within a day or two. Bruising is less common but can last up to two weeks if it happens. If you have a diagnosed salmon allergy, you should not use PDRN, because trace amounts of the source material may remain even after purification. Topical PDRN serums are generally well tolerated, but the injectable format requires a trained practitioner.
References
- Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L, Altavilla D. "Pharmacological Activity and Clinical Use of PDRN." Front Pharmacol. 2017. PMID 28491036 DOI
- Marques C, Porcello A, Cerrano M, Hadjab F, Chemali M, Lourenço K, Hadjab B, Raffoul W. "From Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications of Multifunctional Biomolecules." Biomolecules. 2025. PMID 39858543 DOI
- Veronesi F, Dallari D, Sabbioni G, Carubbi C, Martini L, Fini M. "Polydeoxyribonucleotides (PDRNs) From Skin to Musculoskeletal Tissue Regeneration via Adenosine A2A Receptor Involvement." J Cell Physiol. 2017. PMID 27791262 DOI
- Galeano M, Pallio G, Irrera N, Mannino F, Bitto A, Altavilla D, Vaccaro M, Squadrito G. "Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing." Pharmaceuticals (Basel). 2021. PMID 34832885 DOI
- Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018. PMID 29986520 DOI
- Pak CS, Lee J, Lee H, Jeong J, Kim EH, Jeong J, Choi H, Kim B. "A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow's feet: a new concept of regenerative filler." J Korean Med Sci. 2014. PMID 25473210 DOI
- Lee KWA, Chan KWL, Lee A, Lee CH, Wan J, Wong S, Yi KH. "Polynucleotides in Aesthetic Medicine: A Review of Current Practices and Perceived Effectiveness." Int J Mol Sci. 2024. PMID 39125793 DOI